ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 16 for:    Sandhoff Disease

Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00672022
Recruitment Status : Completed
First Posted : May 6, 2008
Last Update Posted : May 6, 2008
Sponsor:
Collaborator:
Actelion
Information provided by:
Children's Research Institute

May 2, 2008
May 6, 2008
May 6, 2008
July 2004
August 2007   (Final data collection date for primary outcome measure)
Biomarkers (level of GM2 ganglioside, chitotriosidase activity, anti-GM2 antibodies) in plasma, serum and CSF will be measured at initial visit (run-in period), Week 13, and Week 25.
Same as current
No Changes Posted
  • Neurophysiologic Assessment - EEG and BEAR tests will be done at initial visit (run-in period), Week 13, and Week 25.
  • Ophthalmology Assessment - comparision of the "cherry-red" macula changes will be made at initial visit (run-in period) and Week 25.
Same as current
Not Provided
Not Provided
 
Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses
Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset GM2 Gangliosidosis: Single and Steady State Oral Doses
We want to see if Zavesca (or miglustat) is safe and can be tolerated by patients with acute infantile onset GM2 gangliosidosis - classical Tay-Sachs and infantile onset Sandhoff disease. We know that miglustat inhibits the formation of GM2 ganglioside, the compound that is stored in the brains of children with Tay-Sachs and Sandhoff disease. Since it inhibits the synthesis of ganglioside, miglustat may be able to reduce or delay the onset of clinical symptoms.

Specific Aims

The primary objective of the study is to investigate the pharmacokinetics of ZAVESCA® (miglustat, OGT918), when given as a single dose and at steady state, in infantile patients with GM2 gangliosidosis. The secondary objectives are to evaluate the tolerability and safety of single and multiple doses of miglustat and to monitor disease progression using physical and developmental assessments and disease-specific biomarkers.

Interventional
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • GM2 Gangliosidoses
  • Tay-Sachs
  • Sandhoff Disease
Drug: Zavesca (Miglustat)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
Same as current
August 2007
August 2007   (Final data collection date for primary outcome measure)

Inclusion criteria

  1. Diagnosis of GM2 gangliosidosis, confirmed by demonstration of profound deficiency of -hexosaminidase A or A & B in peripheral blood leukocytes or in cultured skin fibroblasts, within the previous 1 year in non-bone marrow transplant recipients who are < 2 years of age, or prior to stem cell transplant in stably engrafted transplant patients who are < 5 years of age.
  2. Onset of characteristic clinical symptoms of the disease before the age of 9 months.
  3. Normal renal and hepatic function.
  4. Written informed consent from parent or legal guardian.

Exclusion criteria

  1. Patients who are unable to comply with the study procedures of this protocol, including the refusal to swallow the food used to mask the taste of the study drug and whose parents are unwilling to administer the drug through a nasogastric or gastrostomy tube.
  2. Patients receiving other investigational agents within 3 months of study initiation.
  3. Patients who are anemic (hemoglobin < 11 g/dl, and/or hematocrit < 34%)
  4. Patients who have a history of significant gastrointestinal disorders, including clinically significant diarrhea (>3 liquid stools per day for > 7 days), without definable cause within 3 months of baseline visit.
  5. Patients with a high probability of dying during the 6-month assessment period of the study.
  6. Patients who in the opinion of the investigator (for whatever reason) are thought to be unsuitable for the study.
Sexes Eligible for Study: All
6 Months to 5 Years   (Child)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00672022
3445
Not Provided
Not Provided
Not Provided
Not Provided
Children's Research Institute
Actelion
Principal Investigator: Cynthia J TIfft, MD, PhD Children's Research Institute
Children's Research Institute
July 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP